Podcasts about cannabinoid therapeutics

EPISODE LINKS: Danielle's Publications: https://www.researchgate.net/profile/Danielle-Mccartney  Lambert Initiative for Cannabinoid Therapeutics: https://www.sydney.edu.au/lambert/ SUPPORT & CONNECT: Elevation Fitness Website: https://elevationfitnessli.com/  Elevation Fitness Instagram: https://www.instagram.com/elevationfitnessli/ 

When you take a prescription medication, it goes into your body, does what it is supposed to and then leaves. Part of leaving the body often involves the medication getting broken down or metabolized by enzymes in the liver. One of the biggest medication metabolizing enzyme systems in the liver is called the Cytochrome P450 enzymes. Why should you care? Because cannabis can effect the Cytochrome P450 enzymes. That could cause there to be too much or too little of a prescription medication in your body to do its job properly. Dr. Lyndsey Anderson and her colleagues at the Lambert Initiative for Cannabinoid Therapeutics in Sydney, Australia have looked at how cannabis and the Cytochrome P450 enzymes interact. Let's have a listen!Lambert Initiative for Cannabinoid Therapeutics - web siteLyndsey Anderson - LinkedInMusic by:Emre Cords-Before We Decided to Fall -YouTube(Yes we got a SOCAN membership to use this song all legal and proper like)Additional Music:Desiree Dorion desireedorion.comMarc Clement - FacebookTranscripts, papers and so much more at: reefermed.ca

Danielle McCartney is a Postdoctoral Research Associate at the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney. Her main role is to coordinate clinical research into the effects of cannabidiol on simulated car driving performance.  Danielle and her colleagues recently published a systematic review of 20 studies that examine the next-day effects of THC. As the study states, “The length of time an individual should wait following cannabis use before performing safety-sensitive tasks, is a critical issue.” Some government agencies and experts recommend individuals avoid performing safety-sensitive tasks for at least 24 hours. It should not surprise you to learn that the data suggests a much shorter impairment window. During our conversation, we discuss: The different types of studies the authors reviewed and the criteria they used to evaluate them The different tests administered to measure impairment How next-day effects of THC compare to acute effects How next-day effects are different in medicinal cannabis patients vs. recreational users What methods are available to determine THC impairment in drivers What is a reasonable impairment window for THC Thank You to This Episode's Sponsor: Medicine Women Health Medicine Women's team of specialists includes Medical Doctors, Naturopaths, Medical Cannabis Experts, Nutritionists and Alternative Health Practitioners. These integrative teams evaluate health issues and design targeted protocols to promote personal healing. Medicine Women's Protocols have successfully alleviated symptoms of Cancer, Auto-Immune Diseases and Neurological Conditions, as well as providing overall Health Rejuvenation. Learn more at www.medicinewomenhealth.com.  Additional Resources The “Next Day” Effects of Cannabis Use: A Systematic Review Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review Lambert Initiative for Cannabinoid Therapeutics Review the Podcast! CannMed Archive CannMed Community Board [Facebook Group]

Host: Monsignor David Rubino, Ph.D.Guest: Sasha Noe, D.O., Ph.D., Advisory Committee Chair and Faculty Member of the LECOM Master of Science in Medical Cannabinoid Therapeutics programDr. Sasha Noe is a physician, researcher, best selling author and international public speaker and discusses the Medical Cannabinoid Therapeutics program as well as her research with cannabis.________Please visit LECOM.edu for to learn more about the educational opportunities available at our institution.

Host: Monsignor David Rubino, Ph.D.Guest: Sasha Noe, D.O., Ph.D., Advisory Committee Chair and Faculty Member of the LECOM Master of Science in Medical Cannabinoid Therapeutics programDr. Sasha Noe is a physician, researcher, best selling author and international public speaker and discusses the Medical Cannabinoid Therapeutics program as well as her research with cannabis.________Please visit LECOM.edu for to learn more about the educational opportunities available at our institution.

A conversation about cannabinoid science and developments in medical cannabis research with Cilla Zhou from the Lambert Initiative for Cannabinoid Therapeutics.

A conversation about cannabinoid science and developments in medical cannabis research with Cilla Zhou from the Lambert Initiative for Cannabinoid Therapeutics.

On this episode, we are joined by Rhys Cohen. Rhys has delivered consulting projects to most of Australia's leading cannabis companies and is currently the Senior Corporate Communications Manager at Cann Group. He sits on the non-executive advisory board of the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney, and was previously editor-at-large at Cannabiz, Australia's leading B2B industry publication. Topics: 1. Politics & Economics of Cannabis 2. Industry Analysis 3. Overview of Australia * Twitter - @TheCannabisRev2 * LinkedIn - @thecannabisreview * Episode Library - https://www.irishmedianetwork.com/the... + Cann-Group https://www.canngrouplimited.com/

When you take a prescription medication, it goes into your body, does what it is supposed to and then leaves. Part of leaving the body often involves the medication getting broken down or metabolized by enzymes in the liver. One of the biggest medication metabolizing enzyme systems in the liver is called the Cytochrome P450 enzymes. Why should you care? Because cannabis can effect the Cytochrome P450 enzymes. That could cause there to be too much or too little of a prescription medication in your body to do its job properly. Dr. Lyndsey Anderson and her colleagues at the Lambert Initiative for Cannabinoid Therapeutics in Sydney, Australia have looked at how cannabis and the Cytochrome P450 enzymes interact. Let's have a listen!Music by:Emre Cords-Before We Decided to Fall https://www.youtube.com/watch?v=orekXjikSG8(Yes we got a SOCAN membership to use thissong all legal and proper like)Additional Music:Desiree Dorionwww.desireedorion.com/Marc Clementhttp://marcclementmusic.com/

We're joined by Dr Danielle McCartney, an Accredited Sports Dietitian & researcher at The Lambert Initiative for Cannabinoid Therapeutics. Danielle provides a fascinating overview of CBD use for sport. What are the potential uses? Is it safe, legal, how do you buy it, and is the hype justified?

(Part 2) What happens when CB1 Receptors are removed from the body? Or when the enzyme (FAAH) that breaks down your own endocannabinoids is no longer present in the body? Our guest, Iain McGregor, Professor of Psychopharmacology at University of Sydney & Academic Director at the Lambert Initiative for Cannabinoid Therapeutics, discusses new findings and what lies ahead in cannabis research. P.S. World's best search engine for Video Cannabis Education = PeriodicSearch.com Schedule 1-on-1 call w/ Wayne (Office Hours, Fri 2-4pm PST) *read details for 1-on-1 calls in this calendar link Send a Message = Contact Us

(Part 1) Sometimes a single story can do more than mountains of research data. Previous decades only allowed the research of cannabis when looking at it's harm potential, however recent times have changed. Our guest, Iain McGregor, Professor of Psychopharmacology at University of Sydney & Academic Director at the Lambert Initiative for Cannabinoid Therapeutics, discusses new findings and what lies ahead. P.S. World's best search engine for Video Cannabis Education = PeriodicSearch.com Schedule 1-on-1 call w/ Wayne (Office Hours, Fri 2-4pm PST) *read details for 1-on-1 calls in this calendar link Send a Message = Contact Us

This week we're joined by Rhys Cohen, Australian Cannabis Consultant, and Editor at Large of Cannabiz Australia.In this episode, Rhys gives us a high level overview of cannabis down-under, including its changing public perceptions, patient access to medical products, and progress towards decriminalisation. → View full show notes, summary, and access resources here: https://www.canverse.global/shownotes/e110About RhysRhys has delivered consulting projects to most of Australia's leading cannabis companies and has worked extensively with the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney. He has presented at numerous industry events including ACannabis (2021); Prohibition Partners Live (2020); and New Frontier Global Cannabis Town Hall (2020). His industry analysis has been cited by Deloitte Access Economics; the Victorian Department of Economic Development, Jobs, Transport and Resources; the Commonwealth Office of Drug Control; the Commonwealth Senate Standing Committee on Community Affairs; and the International Journal of Drug Policy. Rhys has also appeared in ABC News; The Australian Financial Review, The Age; The Sydney Morning Herald; and MJBiz Daily. He is the editor-at-large for Australia's leading industry news platform Cannabiz. And he sits on the Advisory Board of market intelligence and research company FreshLeaf Analytics.Quotables‘[In Australia] the existence of the medical properties of cannabis are not disputed by anyone' 06:31Once it becomes easy and cheap enough here is no reason why other people who aren't medicinal cannabis patients could start accepting cannabis on prescription. That combined with the public change in attitudes towards cannabis legalisation more generally… I think we're approaching a point in which we're going to start having the initial conversation about cannabis law reform' 32:00ResourcesJoin Rhys on LinkedIn: https://www.linkedin.com/in/rhyscohen/Rhys's Website: https://www.rhyscohen.com/Join Rhys onTwitter: https://twitter.com/rhyscohenCannabis Australia: https://www.cannabiz.com.au/

Dr. Ziva Cooper, Director of the UCLA Cannabis Research Initiative, discusses the latest medical cannabis research. She goes into everything from the potential interactive of effects of cannabinoids and terpenes, to the efficacy of cannabidiol (CBD), to sex- and age-dependent differences in how cannabinoids affect the body. USEFUL LINKS:Download the podcast & follow Nick at his website[www.nickjikomes.com]Support the show on Patreon & get early access to episodes[https://www.patreon.com/nickjikomes]Sign up for the weekly Mind & Matter newsletter[http://eepurl.com/hFlc7H]Try MUD/WTR, a mushroom-based coffee alternative[https://www.mudwtr.com/mindmatter]Discount Code ($5 off) = MINDMATTEROrganize your digital highlights & notes w/ Readwise (2 months free w/ subscription)[https://readwise.io/nickjikomes/]Start your own podcast (get $20 Amazon gift card after signup)[https://www.buzzsprout.com/?referrer_id=1507198]Buy Mind & Matter T-Shirts[https://www.etsy.com/shop/OURMIND?ref=simple-shop-header-name&listing_id=1036758072§ion_id=34648633]Connect with Nick Jikomes on Twitter[https://twitter.com/trikomes]​​​Learn more about our podcast sponsor, Dosist[https://dosist.com/]ABOUT Nick Jikomes:Nick is a neuroscientist and podcast host. He is currently Director of Science & Innovation at Leafly, a technology startup in the legal cannabis industry. He received a Ph.D. in Neuroscience from Harvard University and a B.S. in Genetics from the University of Wisconsin-Madison.Support the show (https://www.patreon.com/nickjikomes)

Australians regularly rank as some of the happiest people on Earth, but we also are second highest on the list when it comes to taking antidepressants, so why aren't we talking about this? The Quicky investigates how many of us are using medication to help treat our mental health issues, how it works, and what we can do to break down the stigma surrounding this form of treatment. Subscribe to The Quicky at... https://mamamia.com.au/the-quicky/ CREDITS  Host/Producer: Claire Murphy Executive Producer: Siobhán Moran-McFarlane Audio Producer: Jacob Round Guests: Professor Philip Boyce - Professor of Psychiatry at Westmead Hospital, and Head of the Perinatal Psychiatry Clinical Research Unit at Westmead Hospital in Sydney. Dr Izelle Labuschagne - clinical neuroscientist and a Research Fellow in the Cognition and Emotion Research Centre within the School of Psychology at the Australian Catholic University in Melbourne. Professor Iain McGregor - National Health and Medical Research Council Principal Research Fellow, Professor of Psychopharmacology, and Academic Director of the Lambert Initiative for Cannabinoid Therapeutics. Emmeline - Takes antidepressants to treat ongoing anxiety. CONTACT US Got a topic you'd like us to cover? Send us an email at thequicky@mamamia.com.au Mamamia acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Gadigal people of the Eora Nation. We pay our respects to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander cultures. See omnystudio.com/listener for privacy information.

Vaporize Cannabis.  Get behind the wheel of a car.  Pull out onto the highway.  This is not the beginning of an accident report.  This is a study Dr. Tom Arkell and team ran on an actual highway in the Netherlands.  Dr. Arkell is from Australia, his research is partially supported by the Lambert Iniative and the driving was done near Maastricht University.  The study looked at CBD vs THC vs a combo of THC/CBD vs placebo.  You definitely want to listen to this multinational study if just to hear what "placebo cannabis" is.  Driving and cannabis and Kirk and Trevor!  What more do you need? Music by: Kraftwerk Autobahn  -  https://www.youtube.com/watch?v=iukUMRlaBBE (Yes we got a SOCAN membership to use this song all legal and proper like) Additional Music: Desiree Dorion www.desireedorion.com/ Marc Clement http://marcclementmusic.com/ Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving PerformanceA Randomized Clinical Trial - https://jamanetwork.com/journals/jama/article-abstract/2773562 Cannabis and Driving Webinar - https://youtu.be/GlDikWOshbc Lambert Initiative for Cannabinoid Therapeutics - https://www.sydney.edu.au/lambert/  

Human Enhancement Drug Use, with Aleksi Hupli. Researcher Aleksi Hupli explored cannabis for ADHD and Human Enhancement Drug Use in a report for the Medical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland. Aleksi talked to us about his study, including a discussion of some of the most significant evidence to date supporting the use of cannabis for ADHD. He also mentions a follow-up study he’d like to conduct, to explore the topic more thoroughly. Aleksi lives in Amsterdam, from Lappeenranta, studied in Helsinki, and currently doing his Ph.D. at the University of Tampere. He also works as a freelance video reporter and is a board member at the Finnish Association for Humane Drug Policy and the vice-president of the Amsterdam Society for Medical Social Scientists.

Pretty much every week, we get an email from a new cannabis startup, promoting their latest CBD or THC remedy to treat any number of health conditions, including sleep problems. This boom in new, legal cannabis products is the result of recent legislation to start the process of widespread marijuana decriminalisation, and eventually full legalisation. But whilst the consumer demand is fuelling massive growth in the global cannabis industry, currently, there's little, verging on zero clinical evidence to firmly substantiate many of the health claims made by the new wave of cannabis products hitting the market. So in this episode, we go behind the marketing claims, and look at the real, solid, scientific evidence behind medical cannabis and its efficacy in treating insomnia and a whole host of other sleep disorders including sleep apnea, restless legs syndrome, and even narcolepsy. This episode's guest:   Anastasia Suraev is a clinical research officer at the Lambert Initiative for Cannabinoid Therapeutics, a philanthropically-funded centre for cannabinoid research at the University of Sydney. She is also a PhD candidate at the Woolcock Institute of Medical Research where she is leading a clinical trial assessing the effects of a cannabis-based therapy on sleep in people with chronic insomnia. University of Sydney: https://www.sydney.edu.au/science/about/our-people/academic-staff/anastasia-suraev.html Lambert Initiative for Cannabinoid Therapeutics: https://www.sydney.edu.au/lambert/: Systematic Review: Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies Episode Homepage: http://sleepjunkies.com/cannabis-sleep-medicine/ More Episodes:

Pretty much every week, we get an email from a new cannabis startup, promoting their latest CBD or THC remedy to treat any number of health conditions, including sleep problems. This boom in new, legal cannabis products is the result of recent legislation to start the process of widespread marijuana decriminalisation, and eventually full legalisation. But whilst the consumer demand is fuelling massive growth in the global cannabis industry, currently, there's little, verging on zero clinical evidence to firmly substantiate many of the health claims made by the new wave of cannabis products hitting the market. So in this episode, we go behind the marketing claims, and look at the real, solid, scientific evidence behind medical cannabis and its efficacy in treating insomnia and a whole host of other sleep disorders including sleep apnea, restless legs syndrome, and even narcolepsy. This episode's guest:   Anastasia Suraev is a clinical research officer at the Lambert Initiative for Cannabinoid Therapeutics, a philanthropically-funded centre for cannabinoid research at the University of Sydney. She is also a PhD candidate at the Woolcock Institute of Medical Research where she is leading a clinical trial assessing the effects of a cannabis-based therapy on sleep in people with chronic insomnia. University of Sydney: https://www.sydney.edu.au/science/about/our-people/academic-staff/anastasia-suraev.html Lambert Initiative for Cannabinoid Therapeutics: https://www.sydney.edu.au/lambert/: Systematic Review: Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies Episode Homepage: https://sleepjunkies.com/cannabis-sleep-medicine/ More Episodes:

Tonight the GreenNurses speak with Brooke Andrade about Cannabinoid Therapeutics and Organ Donation. We are looking for a Blood Type O kidney for Brooke. Amy Miller will be calling in to discuss her recent kidney donation to her neighbor (Wow! - True Green Angel) and how cannabis oil (RSO / FECO) helped expedite her healing process.

More about developments in cannabinoid science as a follow on from a previous discussion about medical cannabis. Professor Iain McGregor is Academic Director of the Lambert Initiative for Cannabinoid Therapeutics which is part of the Brain and Mind Centre at the University of Sydney. As well as explaining the human endocannabinoid system and the potential medicinal uses of various components of cannabis plants, Iain comments on the current regulatory approach to medical cannabis in Australia.

People involved in medical cannabis can find themselves in a twilight zone where the law may prevent uses of cannabinoids claimed to have life-saving effects. Professor Iain McGregor explains the vision, stories and studies behind the University of Sydney’s Lambert Initiative for Cannabinoid Therapeutics. Soundbite and transcript at http://sydney.edu.au/news-opinion/news/2017/09/25/is-medical-marijuana-the-next-wonder-drug-podcast.html

Talking about Holistic Nursing and Cannabinoid Therapeutics as Nurse Heather previews her upcoming presentation at the annual conference of the American Holistic Nurses Association.

Cannabis for ADHD, with Aleksi Hupli. Researcher Aleksi Hupli explored cannabis for ADHD in his recent case report Medical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland. Aleksi talked to us about his study, including discussion of some of the most significant evidence to date supporting the use of cannabis for ADHD. He also mentions a follow-up study he'd like to conduct, to explore the topic more thoroughly. Aleksi lives in Amsterdam, from Lappeenranta, studied in Helsinki and currently doing my PhD at the University of Tampere. He also works as a freelance video reporter and is a board member at the Finnish Association for Humane Drug Policy and the vice-president of the Amsterdam Society for Medical Social Scientists.

Talking about Holistic Nursing and Cannabinoid Therapeutics as Nurse Heather previews her upcoming presentation at the annual conference of the American Holistic Nurses Association.